Drug interactions
Cabergoline + Fosamprenavir
Severity: Major
Cabergoline and Fosamprenavir: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Fosamprenavir, which is converted to the CYP3A4-inhibiting protease inhibitor amprenavir (usually given with ritonavir), may raise cabergoline exposure. Ergot derivatives given with strong CYP3A4 inhibitors carry a risk of ergotism, with vasospasm and ischemia. The risk is best documented for other ergots, and cabergoline is less dependent on CYP3A4 metabolism.
What this interaction means in plain words
Cabergoline and Fosamprenavir can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Inhibition of CYP3A4-mediated metabolism of cabergoline by the protease inhibitor, with pharmacokinetic increase in exposure.
What to do
Avoid the combination if an alternative antiretroviral or dopamine agonist is available; otherwise use the lowest cabergoline dose and monitor for nausea, hypotension, and peripheral ischemia.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Cabergoline and Fosamprenavir, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Cabergoline
Frequently asked questions
Can I take Cabergoline with Fosamprenavir?
MediHelp rates the interaction as major. Cabergoline and Fosamprenavir can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Fosamprenavir, which is converted to the CYP3A4-inhibiting protease inhibitor amprenavir (usually given with ritonavir), may raise cabergoline exposure. Ergot derivatives given with strong CYP3A4 inhibitors carry a risk of ergotism, with vasospasm and ischemia. The risk is best documented for other ergots, and cabergoline is less dependent on CYP3A4 metabolism.
How serious is the interaction between Cabergoline and Fosamprenavir?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if an alternative antiretroviral or dopamine agonist is available; otherwise use the lowest cabergoline dose and monitor for nausea, hypotension, and peripheral ischemia.
What other medicines interact with Cabergoline?
MediHelp also lists interactions of Cabergoline with, for example, Benperidol, Chlorpromazine, Clarithromycin. The full list is on the Cabergoline page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
